中樞神經系統的藥物開發:多發性硬化症 是由出版商Espicom Business Intelligence在2008年08月所出版的。
這份英文市場調查報告書包含Pages: 128 價格從美金1040起跳。
多發性硬化症的銷售額預料將在2006年達到49億美金,較前年度增加了8.9%。雖名列中樞神經系統疾病的第5位,但仍吸引許多大規模製藥廠商及生物科技企業大手筆地投資其研究開發的計劃。
以提供醫療儀器、藥品相關資訊而獲全球高度評價的英國市調公司 Espicom Business Intelligence ,彙整多發性硬化症治療的藥物開發動向,並出版綜合報告書"CNS Drug Discoveries: Multiple Sclerosis Chapter"。
此報告書除了說明多發性硬化症的概要與病患動向、各國市場的治療藥銷售動向,也探討主要品牌分析、開發中的新藥等。此報告書的概略架構如下所示。
摘要
背景
- 何謂多發性硬化症、為何對它有興趣呢
- 病患統計
- 病患模式
- 可治療多發性硬化症病患人口預料在2005年至2012年間將以CAGR4.6%的速度成長
- 擴大促進因素
- 擴大風險•阻礙因素
全球多發性硬化症治療藥市場
- 全球銷售的細目
- 美國
- 歐洲
- 日本
- 主要企業
- 2005年及2006年的主要企業與製品
- 2012年的主要企業與製品
- 當今治療法
- 主要品牌分析
- 調整劑
- 現今治療法在2005年至2012年間的銷售預測
- 開發中的新藥
- 第3階段藥劑分析
- 多發性硬化症的症狀
- 第3階段藥劑在2006年至2012年間的銷售預測
- 第2階段藥劑分析
- 第2階段藥劑在2006年至2012年間的銷售預測
- 競爭率分析:製品
- 競爭率分析:企業
- 藥劑開發終止
- 附錄
- 用語
- 參考情報
Abstract
The incidence of multiple sclerosis varies throughout the world, although
there is a significantly higher incidence of the disease found in the Northern
Hemisphere. Find out more in this chapter of CNS Drug Discoveries.
It is estimated that over 350,000 Americans (approximately 1 in 1,000 aged
over 30 years) live with multiple sclerosis (MS) and approximately 3 million
live with it worldwide. However, the prevalence may be higher because of the
uncertainty in diagnosing the condition. Women are twice as susceptible as men
and it is more common in people in northern latitudes over the age of 18
years. In addition, siblings of an individual with multiple sclerosis have a
higher chance of developing the disease.
The incidence of multiple sclerosis varies throughout the world, although
there is a significantly higher incidence of the disease found in the northern
hemisphere. Multiple sclerosis is the most common cause of neurological
disability in young adults in the UK. It is variable in presentation and
progression. Although there is no cure, there are many symptomatic treatments
available. However, many patients do not respond to currently available
products (30%) and the more chronic forms (secondary-progressive MS) are
poorly treated with existing therapies.
Global multiple sclerosis market
The MS market is estimated to be worth US$4.9 billion in 2006 with a growth
rate of 8.9% year-on-year. It is the fifth largest segment of the CNS market
and has attracted considerable R&D investment from big pharma, biotechnology
companies and specialty pharma. The market is currently driven by the use of
six disease-modifying agents: Avonex (Biogen Idec), Betaseron/Betaferon
(Schering AG), Copaxone (Teva), Novatrone (Schering AG), Rebif (Serono/Pfizer)
and Tysabri (Biogen Idec/Elan).
Sales growth will be driven by current drugs gaining broader indications, MS
medicine being prescribed earlier in treatment in clinically-defined multiple
sclerosis patients and the longer-term use of combination therapies as more
classes of drug become available.
Table of Contents
MULTIPLE SCLEROSIS
- EXECUTIVE SUMMARY
- THE FACTS
- What is MS and why are we interested in it?
- PATIENT STATISTICS
- Incidence, diagnosis rates and treatment; now and in the future
- MS categories
- PATIENT MODEL
- The treatable MS patient population will have a CAGR 2005-2012 = 4.6%
- Summary of patient population forecasts
- DRUG GROWTH DRIVERS
- DRUG GROWTH RISKS/DAMPENERS
GLOBAL MS MARKET
- Global CNS Market (US$68.7 billion)
- GLOBAL SALES SPLIT
- Global sales split (2005A)
- US market
- MS US drugs sales split (2005A)
- European market
- MS European drugs sales split (2005A)
- Japanese market
- The major players
- Market share of MS players by sales (Dec 2005A)
- Players and Products in 2005 & 2006
- Players and products in 2012
- CURRENT TREATMENTS
- Leading Brands
- Comparison of Leading MS Agents
- Current Products Patent Exposure
- Patent Exposure of Leading Brands
- ANALYSIS OF LEADING BRANDS
- Disease-modifying agents
- Avonex (Biogen Idec/Genzyme)
- Betaferon/Betaseron (Berlex/Schering AG)
- Copaxone (Teva)
- Rebif (Serono)
- Tysabri
- Novantrone (Serono)
- GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005-2012
- Sales Forecasts of Current Leading MS Drugs
- Model assumptions
- NEW DRUGS IN R&D
- Drugs in Development to Treat MS
- ANALYSIS OF PHASE III DRUGS
- New Drugs in Phase III Development to Treat MS
- Disease-modifying agents
- MS Symptoms
- Campath (Genzyme/Schering AG)
- FTY720 (Novartis)
- Laquinimod (Teva/Active Biotech)
- MBP8298 (BioMS)
- Mylinax (Serono/Ivax)
- Rituxan (Genentech/Biogen Idec/Roche/Chugai/Zenyaju Kogyo)
- Teriflunomide (sanofi-aventis)
- MS Symptoms
- Neurelan (Elan/Acorda)
- Trial MS-F202: Timed 25-foot walk response rate of MS patients treated
with Fampridine SR
- GLOBAL SALES FORECASTS OF PHASE III MS DRUGS 2006-2012
- Sales Forecasts of Phase III Developmental MS Drugs
- Model assumptions
- ANALYSIS OF PHASE II DRUGS
- New Drugs in Early Clinical Development to Treat MS
- Disease-modifying agents
- Vaccines
- Disease-modifying agents
- ABT-874 (Abbott)
- ATL1102 (Antisense/ISIS pharmaceuticals)
- BG-12 (Biogen Idec)
- Daclizumab (Biogen Idec/BioPharma)
- SB-683699 (GlaxoSmithKline/Tanabe Seiyaku)
- Vaccines
- NeuroVax (TIRC)
- Tovaxin (Opexa Therapeutics)
- Other Interesting Phase II Drugs
- GLOBAL SALES FORECASTS OF PHASE II MS DRUGS 2006 - 2012
- Sales Forecasts of Phase II Developmental MS Drugs
- Model assumptions
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- CR Analysis of MS Agents Approved by 2012 - Based on Drug Class
- COMPETITOR RATIO ANALYSIS - COMPANIES
- CR Analysis of MS Agents Approved by 2012 - Based on Company
- WINNERS & LOSERS
- Summary of Key Companies and Drugs in the MS Market by 2012
- Winners
- Losers
- DISCONTINUATION OF DRUGS
- MS Drugs Discontinued from Clinical Development
- MS APPENDIX 1
- Clinical diagnostic test for MS
- MS APPENDIX 2
- Expanded Disability Status Scale (EDSS)
- MS APPENDIX 3
- Phase transition probability
- MS APPENDIX 4
- Patient Model
- Summary of US MS Patient Population Forecasts
- Summary of Europe (Tope 5) MS Patient Population Forecasts
- Summary of Japan MS Patient Population Forecasts
- MS APPENDIX 5
- Global MS Drugs Sales 2005-20012
- Global MS Drug Sales 2005A-2012E
- Ms APPENDIX 6
- Competitor Ratio Analysis Criteria
- Key MS Drugs on the Market by 2012
- MS GLOSSARY
- MS REFERENCES
- ACRONYMNS